Demographics, Disease Characteristics, and Time to Effective Treatment of Patients with Psoriasis in the Ghent PsoPlus Cohort of 2021.

IF 3.5 3区医学 Q1 DERMATOLOGY

Dermatology and Therapy Pub Date : 2024-10-01 Epub Date: 2024-10-04 DOI:10.1007/s13555-024-01277-y

Evelyn Meulewaeter, Anke Eylenbosch, Evelien Verhaeghe, Rani Soenen, Jo Lambert

{"title":"Demographics, Disease Characteristics, and Time to Effective Treatment of Patients with Psoriasis in the Ghent PsoPlus Cohort of 2021.","authors":"Evelyn Meulewaeter, Anke Eylenbosch, Evelien Verhaeghe, Rani Soenen, Jo Lambert","doi":"10.1007/s13555-024-01277-y","DOIUrl":null,"url":null,"abstract":"Introduction: Psoriasis is a chronic immune-mediated skin disease with several comorbidities and a considerable influence on quality of life. Many patients with moderate-to-severe psoriasis are undertreated and have a substantial disease duration before effective treatment is started. This study analyzed patient and disease characteristics and time to effective treatment of patients with psoriasis who consulted PsoPlus. It also examined whether a treat-to-target (T2T) approach, which is implemented in PsoPlus, has an impact on treatment choice and disease progression.Methods: Through a single center, retrospective study, 170 patients in the PsoPlus dedicated clinic were compared at moment of enrollment in PsoPlus and at the last recorded consultation in 2021.Results: Median disease duration at the first PsoPlus consultation was 16.0 (interquartile range (IQR) 19.0) years. There was a significant difference in Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) between the first and the last recorded PsoPlus consultation (PASI 6.0 (IQR 6.4) vs. 0.6 (IQR 2.6); DLQI 11 (IQR 11) vs. 2 (IQR 6); p < 0.001). A weak positive Spearman correlation (rs) was found between disease duration and PASI at the first PsoPlus consultation (rs = 0.175; p = 0.034), while a weak negative correlation (rs = - 0.2; p = 0.013) was found at the last registered PsoPlus consultation. Patients with a disease duration of more than 20 years had significantly more switches of treatment than those with a shorter disease duration (p < 0.001). Median time from psoriasis onset until PASI ≤ 2 was 16.0 years. Median time from the first PsoPlus consultation until PASI ≤ 2 was 7.0 months.Conclusion: The PsoPlus program with its T2T approach effectively improves clinical outcomes and quality of life for patients with psoriasis in a relatively short period, emphasizing the value of a structured, personalized treatment plan for long-term management.","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2889-2903"},"PeriodicalIF":3.5000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480273/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-024-01277-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Psoriasis is a chronic immune-mediated skin disease with several comorbidities and a considerable influence on quality of life. Many patients with moderate-to-severe psoriasis are undertreated and have a substantial disease duration before effective treatment is started. This study analyzed patient and disease characteristics and time to effective treatment of patients with psoriasis who consulted PsoPlus. It also examined whether a treat-to-target (T2T) approach, which is implemented in PsoPlus, has an impact on treatment choice and disease progression.

Methods: Through a single center, retrospective study, 170 patients in the PsoPlus dedicated clinic were compared at moment of enrollment in PsoPlus and at the last recorded consultation in 2021.

Results: Median disease duration at the first PsoPlus consultation was 16.0 (interquartile range (IQR) 19.0) years. There was a significant difference in Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) between the first and the last recorded PsoPlus consultation (PASI 6.0 (IQR 6.4) vs. 0.6 (IQR 2.6); DLQI 11 (IQR 11) vs. 2 (IQR 6); p < 0.001). A weak positive Spearman correlation (r_s) was found between disease duration and PASI at the first PsoPlus consultation (r_s = 0.175; p = 0.034), while a weak negative correlation (r_s = - 0.2; p = 0.013) was found at the last registered PsoPlus consultation. Patients with a disease duration of more than 20 years had significantly more switches of treatment than those with a shorter disease duration (p < 0.001). Median time from psoriasis onset until PASI ≤ 2 was 16.0 years. Median time from the first PsoPlus consultation until PASI ≤ 2 was 7.0 months.

Conclusion: The PsoPlus program with its T2T approach effectively improves clinical outcomes and quality of life for patients with psoriasis in a relatively short period, emphasizing the value of a structured, personalized treatment plan for long-term management.

查看原文本刊更多论文

2021 年根特 PsoPlus 队列中银屑病患者的人口统计、疾病特征和有效治疗时间。

简介银屑病是一种免疫介导的慢性皮肤病，有多种并发症，对生活质量有很大影响。许多中重度银屑病患者治疗不足，在开始有效治疗前病程较长。本研究分析了就诊于 PsoPlus 的银屑病患者的病情特征和有效治疗时间。研究还探讨了 PsoPlus 采用的 "靶向治疗"（T2T）方法是否会对治疗选择和疾病进展产生影响：通过单中心回顾性研究，对PsoPlus专科门诊的170名患者在加入PsoPlus时和2021年最后一次就诊记录进行了比较：首次接受 PsoPlus 诊疗时的中位病程为 16.0 年（四分位距（IQR）为 19.0 年）。牛皮癣面积和严重程度指数（PASI）和皮肤科生活质量指数（DLQI）在首次和最后一次 PsoPlus 咨询记录之间存在明显差异（PASI 6.0 (IQR 6.4) vs. 0.6 (IQR 2.6)；DLQI 11 (IQR 11) vs. 2 (IQR 6)；PASI 6.0 (IQR 6.4) vs. 0.6 (IQR 2.6)；DLQI 11 (IQR 11) vs. 0.6 (IQR 2.6)）。在第一次 PsoPlus 会诊时，病程与 PASI 之间发现了微弱的负相关（rs = 0.175；p = 0.034），而在最后一次登记的 PsoPlus 会诊时则发现了微弱的负相关（rs = - 0.2；p = 0.013）。与病程较短的患者相比，病程超过 20 年的患者接受治疗的次数明显较多（p 结论：PsoPlus 计划是一种有效的治疗方法，它能帮助患者在最短的时间内获得最佳治疗效果：采用 T2T 方法的 PsoPlus 计划能在较短时间内有效改善银屑病患者的临床疗效和生活质量，强调了结构化、个性化治疗计划在长期管理中的价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatology and Therapy Medicine-Dermatology

CiteScore

6.00

自引率

8.80%

发文量

187

审稿时长

6 weeks

期刊介绍： Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.